Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
BrasilAgro Announces Annual and Extraordinary Shareholders Meeting

BrasilAgro Announces Annual and Extraordinary Shareholders Meeting

BitgetBitget2026/10/15 14:10
  • BrasilAgro will hold its annual and extraordinary shareholders’ meeting exclusively online on October 21, 2026.
  • Shareholders will vote on R$ 30 million in interim dividends from reserves, equivalent to R$ 0.3012 per common share.
  • The agenda includes absorbing wholly owned Agrifirma Agro without increasing share capital, with effectiveness proposed for October 31, 2026.
  • Proposals include an annual management compensation ceiling of R$ 18.68 million for the fiscal year beginning July 1, 2026.
  • Shareholders will also consider annual financial statements, fiscal council elections and R$ 404,143 in fiscal council compensation.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BrasilAgro - Companhia Brasileira de Propriedades Agrícolas published the original content used to generate this news brief on October 15, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

The US FDA requires semaglutide, tirzepatide, and other GLP-1 drugs to include new warnings about the risk of eye disease.

NAION is an eye disease that can cause sudden, painless loss of vision, with some patients potentially experiencing permanent visual impairment. The drugs involved include products from Eli Lilly and Novo Nordisk. According to analysts at Citi, the incidence of NAION is relatively low, and given the significant benefits of GLP-1 drugs in weight control and blood sugar management, the actual impact on prescription behavior is expected to be limited. On Monday, the stock prices of Eli Lilly and Novo Nordisk increased, with the news not causing any significant impact on their share prices.

华尔街见闻•2026/11/09 22:12